The determinants and consequences of excessive oral drug self-administration by schedule-induced polydipsia will be explored, emphasizing oral cocaine (COC) and benzodiazepine (BZ) abuse variables and fine-motor performance consequences: (A: COC) (1) The amelioration of excessive COC intake by acute and chronic treatment with possible therapeutic agents (e.g., desipramine, mazindol) and by (2) alternatives to COC ingestion (e.g., other solutions, activity wheel). (3) Exacerbation of COC abuse by injections of nicotine (NIC) and caffeine (CAF). (4) The gateways to exacerbated COC abuse by first instituting a history of licit-drug polydipsia (NIC, CAF), and (5) possible behavioral immunization (history of situational alternatives) against COC abuse acquisition. The consequences of acute and chronic injection and withdrawal of COC for discriminative motor performance, as well as COC interactions with NIC and CAF. (B: BZ) (1) The amelioration of excessive BZ intake by blockers (Ro 15-1788, CGS 8216) and (2) its exacerbation by CAF or a history of sedative (ethanol) abuse. (3) Acute and chronic drug anxiolytic action evaluation by a method employing the exaggerated ingestion of NaC1 solutions by such agents. (3) The fine motor control consequences of daily rebound from chronic exposure to midazolam (e.g., as perhaps exaggerated by inverse agonist [FG 7142] probes) and of midazolam-CAF interactions. For both COC and BZs, serum levels of drug and metabolites will be measured, both with respect to chronic amounts abused and the levels associated with motor performance disruption.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Scientist Award (K05)
Project #
5K05DA000142-04
Application #
3075469
Study Section
Special Emphasis Panel (SRCD (26))
Project Start
1990-01-01
Project End
1994-12-31
Budget Start
1993-01-01
Budget End
1993-12-31
Support Year
4
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Rutgers University
Department
Type
Schools of Arts and Sciences
DUNS #
038633251
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Wang, Q; Simpao, A; Sun, L et al. (2001) Contribution of the active metabolite, norcocaine, to cocaine's effects after intravenous and oral administration in rats: pharmacodynamics. Psychopharmacology (Berl) 153:341-52
Lau, C E; Sun, L; Wang, Q et al. (2000) Oral cocaine pharmacokinetics and pharmacodynamics in a cumulative-dose regimen: pharmacokinetic-pharmacodynamic modeling of concurrent operant and spontaneous behavior within an operant context. J Pharmacol Exp Ther 295:634-43
Lobarinas, E; Falk, J L (2000) Comparison of benzodiazepines and the non-benzodiazepine agents zolpidem and zaleplon with respect to anxiolytic action as measured by increases in hypertonic NaCl-solution drinking in rats. Psychopharmacology (Berl) 149:176-80
Lau, C E; Ma, F; Foster, D M et al. (1999) Pharmacokinetic-pharmacodynamic modeling of the psychomotor stimulant effect of cocaine after intravenous administration: timing performance deficits. J Pharmacol Exp Ther 288:535-43
Lobarinas, E; Falk, J L (1999) Dose-dependent effects but not sensitization of DRL 45-s performance by oral d-amphetamine with cumulative- and repeated-dosing regimens. Behav Pharmacol 10:739-46
Ma, F; Falk, J L; Lau, C E (1999) Cocaine pharmacodynamics after intravenous and oral administration in rats: relation to pharmacokinetics. Psychopharmacology (Berl) 144:323-32
Lobarinas, E; Lau, C E; Falk, J L (1999) Sensitization of operant behavior to oral cocaine with increasing- and repetitive-dose regimens. Behav Pharmacol 10:15-26
Lau, C E; Wang, Y; Sun, L et al. (1999) Pharmacokinetic determinants of cocaine's differential effects on locomotor and operant behavior. Eur J Pharmacol 381:85-92
Falk, J L; Yosef, E; Schwartz, A et al. (1999) Establishing oral preference for quinine, phencyclidine and caffeine solutions in rats. Behav Pharmacol 10:27-38
Ma, F; Falk, J L; Lau, C E (1999) Within-subject variability in cocaine pharmacokinetics and pharmacodynamics after intraperitoneal compared with intravenous cocaine administration. Exp Clin Psychopharmacol 7:3-12

Showing the most recent 10 out of 25 publications